Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771730 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
A Phase 1 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02771730 is a Phase 1 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 20 participants.
The verdict
NCT02771730, a Phase 1 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response. Researchers want to see how the immune system will respond to these vaccines as well as if they are safe to give to people. Participants cannot get HIV from these vaccines. However, researchers also want to see if the vaccine's adenovirus is contagious. Adenoviruses cause cold symptoms or mild eye infections, therefore household and intimate contacts will be asked to participate as well.
Interventions
- OTHER Placebo Comparator
- BIOLOGICAL Ad4-mgag
- BIOLOGICAL Ad4-EnvC150
- BIOLOGICAL AIDSVAX B/E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02771730
The ClinicalTrials.gov registry entry for NCT02771730 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator is the first listed.
NCT02771730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02771730 about?
NCT02771730 is a clinical study titled "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults". The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response. Researchers want to see how the immune system will respond to these vaccines as well as if they are s...
What is the current status of trial NCT02771730?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02771730?
The interventions under investigation include: Placebo Comparator (OTHER), Ad4-mgag (BIOLOGICAL), Ad4-EnvC150 (BIOLOGICAL), AIDSVAX B/E (BIOLOGICAL).
Who is sponsoring clinical trial NCT02771730?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.